<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00558675</url>
  </required_header>
  <id_info>
    <org_study_id>ITL-001-HMC</org_study_id>
    <nct_id>NCT00558675</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy</brief_title>
  <official_title>A Phase I/II Study of Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStim) Conjugated With CD3/CD28-coated Microbeads in Patients With Relapsed or Refractory Hematological Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovative Therapies, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Immunovative Therapies, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and anti-tumor effects of an
      experimental immunotherapy drug, called AlloStim, which is intentionally mis-matched immune
      cells which are designed to elicit the same anti-tumor mechanism that occurs in allogeneic
      bone marrow/stem cell mini-transplant (BMT) procedures, without the toxicity associated with
      graft vs. host disease (GVHD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AlloStim is combination biological drug and medical device formulation consisting of
      allogeneic immune cells that have been expanded and differentiated ex-vivo. These cells are
      conjugated to monoclonal antibody coated microparticles prior to infusion. The immune cells
      are living CD4+ memory Th1-like T-cells (T-Stim) that are differentiated from precursors
      purified from normal donor blood. AlloStim is a composition of T-Stim cells conjugated to
      paramagnetic epoxy covered microparticles (4.5micron) with covalently bound
      anti-CD3/anti-CD28 monoclonal antibodies (Dynabeads® ClinExVivo™ CD3/CD28) at a 2:1 bead:cell
      ratio. The T-Stim cells are intentionally mismatched to the recipient.

      The graft vs. tumor (GVT) effect that occurs after allogeneic bone marrow transplant (BMT) is
      a curative therapy for advanced hematological malignancy but the clinical application of GVT
      is severely limited by graft vs. host disease (GVHD) toxicity. AlloStim is designed to elicit
      the &quot;mirror&quot; of the GVT/GVHD effects in the host immune system. Rather than trying to
      separate these effects, we have proposed that the effects could remain associated and
      &quot;mirrored&quot; onto the host immune system creating linked host vs. tumor (HVT) and host vs.
      graft (HVG) effects. We hypothesized that allogeneic Th1 memory cells activated at time of
      infusion to produce type 1 cytokines and express CD40L would elicit HVT/HVG &quot;mirror effects&quot;
      in immunocompetent cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of toxicity related to AlloStim infusion in accordance with NCI Common Toxicity Criteria v.3</measure>
    <time_frame>Within first 48 hours post infusion, at 30 days and at 60 days post infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation and reporting of anti-tumor response will be conducted in accordance with internationally accepted criteria for the disease indication being evaluated</measure>
    <time_frame>30 days and 60 days post infusion and yearly thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological Response</measure>
    <time_frame>30 days, 60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hematological Malignancy</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of AlloStim</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous AlloStim infusion on day 1 and day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous AlloStim infusion on day 1, day 7 and day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous AlloStim infusion on day 1, day 7, day 14 and day 21</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>single intravenous infusion of 1 x 10^9 AlloStim cells</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7 and day 14</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AlloStim</intervention_name>
    <description>Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7, day 14 and day 21</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed hematological malignancy

          -  unresponsive to chemotherapy and/or recurrence after autologous transplant

          -  adequate kidney, liver, lung and heart function

        Exclusion Criteria:

          -  prior allogeneic transplant

          -  immunosuppressive therapy for concurrent medical condition

          -  active viral infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Michael Har-Noy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immunovative Therapies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah-Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.immunovative.co.il</url>
    <description>Immunovative Therapies. Ltd</description>
  </link>
  <reference>
    <citation>Har-Noy M, Slavin S. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement? Med Hypotheses. 2008;70(6):1186-92. Epub 2007 Dec 3.</citation>
    <PMID>18054441</PMID>
  </reference>
  <reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Slavin S. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity. Leuk Res. 2008 Dec;32(12):1903-13. doi: 10.1016/j.leukres.2008.05.007. Epub 2008 Jun 18.</citation>
    <PMID>18565579</PMID>
  </reference>
  <reference>
    <citation>Har-Noy M, Zeira M, Weiss L, Fingerut E, Or R, Slavin S. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leuk Res. 2009 Apr;33(4):525-38. doi: 10.1016/j.leukres.2008.08.017. Epub 2008 Oct 1.</citation>
    <PMID>18834631</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2007</study_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkins Lymphoma</keyword>
  <keyword>Hodgkins Lymphoma</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Chronic Myeloid Leukemia</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Allogeneic Cell Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

